News
IMMX
2.290
-0.43%
-0.010
IMMIX BIOPHARMA INC: ON TRACK FOR NEXT PROGRAM UPDATE IN Q1 2025
Reuters · 2h ago
IMMIX BIOPHARMA ACCELERATES ENROLLMENT IN U.S. AL AMYLOIDOSIS TRIAL OF NXC-201 CAR-T
Reuters · 2h ago
Weekly Report: what happened at IMMX last week (1230-0103)?
Weekly Report · 1d ago
Immix Biopharma Price Target Maintained With a $7.00/Share by HC Wainwright & Co.
Dow Jones · 1d ago
HC Wainwright & Co. Reiterates Buy on Immix Biopharma, Maintains $7 Price Target
Benzinga · 1d ago
Analysts Offer Insights on Healthcare Companies: Acumen Pharmaceuticals (ABOS) and Immix Biopharma, Inc. (IMMX)
TipRanks · 1d ago
Weekly Report: what happened at IMMX last week (1223-1227)?
Weekly Report · 12/30/2024 12:10
Weekly Report: what happened at IMMX last week (1216-1220)?
Weekly Report · 12/23/2024 12:19
Immix Biopharma Reports Promising Initial Clinical Data for NXC-201 in Phase 1b/2 NEXICART-2 Trial for Relapsed/Refractory AL Amyloidosis
Barchart · 12/19/2024 18:44
Immix Biopharma announces data from four patients in NEXICART-2 U.S. trial
TipRanks · 12/19/2024 14:40
IMMIX BIOPHARMA ANNOUNCES POSITIVE U.S. CLINICAL DATA FROM FIRST FOUR PATIENTS IN NEXICART-2 U.S. TRIAL OF STERICALLY-OPTIMIZED CAR-T NXC-201 IN RELAPSED/REFRACTORY LIGHT CHAIN (AL) AMYLOIDOSIS
Reuters · 12/19/2024 14:35
Immix Biopharma Announces Promising Clinical Results for CAR-T Therapy NXC-201 in Treating Relapsed/Refractory AL Amyloidosis
Barchart · 12/16/2024 19:00
Immix Biopharma announces publication of NXC-201 clinical results
TipRanks · 12/16/2024 14:55
Immix Biopharma Publishes NXC-201 Clinical Results In Journal Of Clinical Oncology
Benzinga · 12/16/2024 14:51
Weekly Report: what happened at IMMX last week (1209-1213)?
Weekly Report · 12/16/2024 12:20
Journal of Clinical Oncology Publishes NXC-201 Positive Clinical Results in relapsed/refractory AL Amyloidosis
Barchart · 12/16/2024 08:48
Immix Biopharma Reports 75% Complete Response Rate and 31.5-Month Response Duration for CAR-T NXC-201 in Relapsed/Refractory AL Amyloidosis at ASH 2024
Barchart · 12/10/2024 18:58
Immix Biopharma reports 75% CRR for NXC-201 in r/r AL amyloidosis patients
TipRanks · 12/10/2024 14:45
IMMIX BIOPHARMA ANNOUNCES 75% COMPLETE RESPONSE RATE (N=16); 31.5 MONTHS BEST RESPONSE DURATION (ONGOING) FOR CAR-T NXC-201 IN RELAPSED/REFRACTORY AL AMYLOIDOSIS PATIENTS AT ASH 2024
Reuters · 12/10/2024 14:39
Immix Biopharma Announces 75% Complete Response Rate (n=16); 31.5 months Best Response Duration (ongoing) for CAR-T NXC-201 in Relapsed/Refractory AL Amyloidosis Patients at ASH 2024
Barchart · 12/10/2024 08:39
More
Webull provides a variety of real-time IMMX stock news. You can receive the latest news about Immix Biopharma Inc through multiple platforms. This information may help you make smarter investment decisions.
About IMMX
Immix Biopharma, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on the application of chimeric antigen receptor cell therapy (CAR- T) in light chain (AL) Amyloidosis and autoimmune disease. The Company's lead cell therapy asset is CAR-T NXC-201 for autoimmune disease, relapsed/refractory AL Amyloidosis, and relapsed/refractory multiple myeloma, which is being evaluated in its ongoing Phase Ib/IIa NEXICART-1 (NCT04720313) clinical trial. Its tissue specific therapeutic IMX-110 is in clinical trials as a monotherapy, and in combination with tislelizumab (BeiGene anti-PD-1 - IMMINENT-01 NCT05840835) for advanced solid tumors, such as relapsed/refractory colorectal cancer (CRC). IMX-110 in Phase Ib/IIa clinical trials, is a Tissue-Specific Therapeutic with TME Normalization, a technology that the Company is developing initially for mCRC and Soft Tissue Sarcoma (STS).